These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38606958)

  • 1. Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
    Walsh EE; Falsey AR; Zareba AM; Jiang Q; Gurtman A; Radley D; Gomme E; Cooper D; Jansen KU; Gruber WC; Swanson KA; Schmoele-Thoma B
    J Infect Dis; 2024 Apr; ():. PubMed ID: 38606958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
    Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    Walsh EE; Falsey AR; Scott DA; Gurtman A; Zareba AM; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Radley D; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Apr; 225(8):1357-1366. PubMed ID: 34932102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    Falsey AR; Walsh EE; Scott DA; Gurtman A; Zareba A; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Jiang Q; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Jun; 225(12):2056-2066. PubMed ID: 34931667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
    J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    Baber J; Arya M; Moodley Y; Jaques A; Jiang Q; Swanson KA; Cooper D; Maddur MS; Loschko J; Gurtman A; Jansen KU; Gruber WC; Dormitzer PR; Schmoele-Thoma B
    J Infect Dis; 2022 Dec; 226(12):2054-2063. PubMed ID: 35543281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    Simões EAF; Center KJ; Tita ATN; Swanson KA; Radley D; Houghton J; McGrory SB; Gomme E; Anderson M; Roberts JP; Scott DA; Jansen KU; Gruber WC; Dormitzer PR; Gurtman AC
    N Engl J Med; 2022 Apr; 386(17):1615-1626. PubMed ID: 35476650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Otsuki T; Akada S; Anami A; Kosaka K; Munjal I; Baber J; Shoji Y; Aizawa M; Swanson KA; Gurtman A
    Vaccine; 2024 Jun; ():. PubMed ID: 38853036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    Peterson JT; Zareba AM; Fitz-Patrick D; Essink BJ; Scott DA; Swanson KA; Chelani D; Radley D; Cooper D; Jansen KU; Dormitzer PR; Gruber WC; Gurtman A
    J Infect Dis; 2022 Jun; 225(12):2077-2086. PubMed ID: 34637519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
    Ruckwardt TJ; Morabito KM; Phung E; Crank MC; Costner PJ; Holman LA; Chang LA; Hickman SP; Berkowitz NM; Gordon IJ; Yamshchikov GV; Gaudinski MR; Lin B; Bailer R; Chen M; Ortega-Villa AM; Nguyen T; Kumar A; Schwartz RM; Kueltzo LA; Stein JA; Carlton K; Gall JG; Nason MC; Mascola JR; Chen G; Graham BS;
    Lancet Respir Med; 2021 Oct; 9(10):1111-1120. PubMed ID: 33864736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
    Walsh EE; Pérez Marc G; Zareba AM; Falsey AR; Jiang Q; Patton M; Polack FP; Llapur C; Doreski PA; Ilangovan K; Rämet M; Fukushima Y; Hussen N; Bont LJ; Cardona J; DeHaan E; Castillo Villa G; Ingilizova M; Eiras D; Mikati T; Shah RN; Schneider K; Cooper D; Koury K; Lino MM; Anderson AS; Jansen KU; Swanson KA; Gurtman A; Gruber WC; Schmoele-Thoma B;
    N Engl J Med; 2023 Apr; 388(16):1465-1477. PubMed ID: 37018468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
    Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    Schmoele-Thoma B; Zareba AM; Jiang Q; Maddur MS; Danaf R; Mann A; Eze K; Fok-Seang J; Kabir G; Catchpole A; Scott DA; Gurtman AC; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA
    N Engl J Med; 2022 Jun; 386(25):2377-2386. PubMed ID: 35731653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
    Beran J; Lickliter JD; Schwarz TF; Johnson C; Chu L; Domachowske JB; Van Damme P; Withanage K; Fissette LA; David MP; Maleux K; Schmidt AC; Picciolato M; Dieussaert I
    J Infect Dis; 2018 Apr; 217(10):1616-1625. PubMed ID: 29401325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
    Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
    Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
    Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
    Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
    Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    Kampmann B; Madhi SA; Munjal I; Simões EAF; Pahud BA; Llapur C; Baker J; Pérez Marc G; Radley D; Shittu E; Glanternik J; Snaggs H; Baber J; Zachariah P; Barnabas SL; Fausett M; Adam T; Perreras N; Van Houten MA; Kantele A; Huang LM; Bont LJ; Otsuki T; Vargas SL; Gullam J; Tapiero B; Stein RT; Polack FP; Zar HJ; Staerke NB; Duron Padilla M; Richmond PC; Koury K; Schneider K; Kalinina EV; Cooper D; Jansen KU; Anderson AS; Swanson KA; Gruber WC; Gurtman A;
    N Engl J Med; 2023 Apr; 388(16):1451-1464. PubMed ID: 37018474
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.